CA: A Cancer Journal for Clinicians最新文献

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers","authors":"Rana R. McKay MD,&nbsp;Sumanta Pal MD,&nbsp;Wanling Xie MS,&nbsp;David Aggen MD, PhD,&nbsp;Laurence Albiges MD, PhD,&nbsp;Andrea Apolo MD,&nbsp;Michael B. Atkins MD,&nbsp;Rick Bangs MBA, PMP,&nbsp;Kathryn E. Beckermann MD, PhD,&nbsp;Joaquim Bellmunt MD, PhD,&nbsp;Stephanie A. Berg DO,&nbsp;Mehmet A. Bilen MD,&nbsp;David Braun MD, PhD,&nbsp;Maria I. Carlo MD,&nbsp;Jason Efstathiou MD, DPhil,&nbsp;Matthew Galsky MD,&nbsp;Petros Grivas MD, PhD,&nbsp;Shilpa Gupta MD,&nbsp;Naomi Haas MD,&nbsp;A. Ari Hakimi MD,&nbsp;Hans Hammers MD, PhD,&nbsp;Daniel Y. C. Heng MSC,&nbsp;Michelle Hirsch MD, PhD,&nbsp;Gopakumar Iyer MD,&nbsp;Eric Jonasch MD,&nbsp;Vadim S. Koshkin MD,&nbsp;Oleksandr N. Kryvenko MD,&nbsp;Bryan Lewis JD,&nbsp;Roger Li MD,&nbsp;Surena Matin MD,&nbsp;Benjamin Maughan MD, PharmD,&nbsp;David F. McDermott MD,&nbsp;Bradley McGregor MD,&nbsp;Joshua Meeks MD, PhD,&nbsp;Matthew Milowsky MD,&nbsp;Robert Motzer MD,&nbsp;Andrea Necchi MD,&nbsp;Dan Petrylak MD,&nbsp;Sima Porten MD, MPH,&nbsp;Thomas Powles MBBS, MRCP, MD,&nbsp;Brian Rini MD,&nbsp;Brian Shuch MD,&nbsp;Arlene Siefker-Radtke MD,&nbsp;Guru Sonpavde MD,&nbsp;S. Srikala Sridhar MD,&nbsp;Cristina Suarez MD, PhD,&nbsp;Chad Tang MD,&nbsp;Abhishek Tripathi MD,&nbsp;Michiel S. Van Der Heijden MD, PhD,&nbsp;Martin Voss MD,&nbsp;Wenxin Xu MD,&nbsp;Tian Zhang MD,&nbsp;Jonathan Rosenberg MD,&nbsp;Toni K. Choueiri MD","doi":"10.3322/caac.70052","DOIUrl":"10.3322/caac.70052","url":null,"abstract":"<p>The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence-based expert consensus recommendations for optimal management. A multidisciplinary panel of 51 experts participated in a modified Delphi process addressing questions developed through iterative consensus-building covering RCC and UTC management. Voting occurred before and after the conference, and analyses focused on postmeeting responses. Consensus was defined as ≥75% agreement, with strong consensus as &gt;90%. Strong consensus was found on the use of adjuvant pembrolizumab for higher risk RCC (pathologic T2 [pT2], grade 4; pT3–pT4, any grade; pTXN1; or fully resected metastatic disease) and on neoadjuvant therapy before cystectomy for localized UTC. There was strong consensus on the use of enfortumab vedotin plus pembrolizumab as frontline therapy for metastatic UTC and the use of platinum-based chemotherapy postprogression in biomarker-negative UTC. For RCC, there was consensus on the role of single-agent vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy after progression on frontline immune checkpoint inhibitor/vascular endothelial growth factor receptor–tyrosine kinase inhibitor therapy or dual immune checkpoint inhibitor therapy. However, there was a lack of consensus on other critical areas in the management of RCC and UTC. The 2025 Advanced Urologic Cancer Consensus Conference provides evidence-informed guidance for complex clinical scenarios while identifying critical research priorities. The group recognizes that the lack of consensus across multiple areas highlights the need for improved patient selection and prospective studies enabling optimal combination and sequencing approaches. This iterative annual process will address evolving treatment paradigms to optimize outcomes.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen therapy for chronic radiotherapy-related adverse effects: A clinically focused review","authors":"Cas Stefaan Dejonckheere MD,&nbsp;Lukas Käsmann MD, MHBA,&nbsp;Leonard Christopher Schmeel MD, MHBA,&nbsp;Stefanie Walter MSc, MBH,&nbsp;Teresa Anzböck MD,&nbsp;Sven Dreyer MD,&nbsp;Gustavo Renato Sarria MD, MHBA,&nbsp;Eleni Gkika MD, MBA,&nbsp;Julian Philipp Layer MD, MHBA","doi":"10.3322/caac.70058","DOIUrl":"10.3322/caac.70058","url":null,"abstract":"<p>Radiotherapy is a cornerstone of modern oncologic care, yet its sequelae can significantly impair survivors' quality of life. Chronic radiation-induced conditions—including skin fibrosis, bone necrosis, radiation cystitis, and proctitis—pose substantial challenges for both patients and caregivers, particularly in the context of improving long-term cancer survival. Hyperbaric oxygen therapy, characterized by the promotion of angiogenesis, fibroblast activation, and tissue remodeling in hypoxic environments, has emerged as a potential adjunctive treatment for mitigating these late effects. Herein, the authors critically evaluate randomized trials, cohort studies, and real-world data while highlighting gaps in knowledge, including patient selection, optimal treatment protocols, and long-term outcomes. In addition, they discuss practical considerations and health system implications of the integration of hyperbaric oxygen therapy into survivorship care. The objective of this review is to provide clinicians with an evidence-informed framework to guide decision making in the multidisciplinary management of radiation-related late effects.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145729117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148073825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors","authors":"Mohamed E. Abdelsalam MD,&nbsp;Kamran Ahrar MD,&nbsp;Rahul A. Sheth MD,&nbsp;Ketan Y. Shah MD,&nbsp;Steven Yevich MD,&nbsp;Varshana Gurusamy MD,&nbsp;Bruno C. Odisio MD,&nbsp;Alda L. Tam MD,&nbsp;Armeen Mahvash MD,&nbsp;Peiman Habibollahi MD","doi":"10.3322/caac.70051","DOIUrl":"10.3322/caac.70051","url":null,"abstract":"<p>Interventional radiology (IR) is a rapidly evolving medical field that combines advanced imaging with minimally invasive techniques for both diagnosis and treatment. Interventional oncology (IO), a subspecialty of IR, focuses on the minimally invasive, image-guided intervention for cancer and cancer-related conditions. IR plays an important and increasingly recognized role within the multidisciplinary care of patients with cancer, contributing meaningfully to diagnosis, therapy, and palliation. IO therapies, particularly tumor ablation and transarterial embolization, aim to target tumors directly while preserving surrounding healthy tissue. These therapies are increasingly supported by clinical guidelines and have shown favorable outcomes in cancers such as hepatocellular carcinoma, renal cell carcinoma, and metastatic colorectal cancer. This review focuses on the role of minimally invasive, image-guided, locoregional IR therapies for patients who have cancer.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148070573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness","authors":"Susana M. Campos MD, MPH,&nbsp;Jessica DiSilvestro MD,&nbsp;Stephanie V. Blank MD","doi":"10.3322/caac.70057","DOIUrl":"10.3322/caac.70057","url":null,"abstract":"&lt;p&gt;For patients with ovarian, peritoneal, and fallopian tube carcinoma, completing first-line treatment, maintenance therapy aims to stave off the risk of recurrence with the hope it will improve overall survival. Multiple trials, including the Gynecologic Oncology Group GOG-0218 trial,&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; which investigated the vascular endothelial growth factor inhibitor (VEGFi) bevacizumab; SOLO1&lt;span&gt;&lt;sup&gt;3-5&lt;/sup&gt;&lt;/span&gt; (olaparib; ClinicalTrials.gov identifier NCT01844986); PRIMA&lt;span&gt;&lt;sup&gt;6, 7&lt;/sup&gt;&lt;/span&gt; (niraparib; (ClinicalTrials.gov identifier NCT02655016); and PAOLA-1&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; (bevacizumab plus olaparib (ClinicalTrials.gov identifier NCT24777644) have uniquely and independently played pivotal roles in shaping the role of maintenance therapy in this patient population.&lt;/p&gt;&lt;p&gt;Specifically, PAOLA-1&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; investigated whether there was value in a combined maintenance strategy. This trial randomly assigned people with ovarian cancer (both homologous recombination-proficient [HRP] and homologous recombination-deficient [HRD]) to receive either maintenance bevacizumab plus the poly (ADP-ribose polymerase) inhibitor (PARPi) olaparib or bevacizumab plus placebo. Compared with bevacizumab plus placebo, there was a significant benefit in progression-free survival (PFS) among patients with HRD disease who received bevacizumab plus olaparib (hazard ratio [HR], 0.41; 95% confidence interval [CI], 0.32–0.54). Among those with HRD disease because of a &lt;i&gt;BRCA1&lt;/i&gt; or &lt;i&gt;BRCA2&lt;/i&gt;  mutation, combined treatment resulted in an overall survival benefit (HR, 0.60; 95% CI, 0.39–0.93); this was not reported among those who had HRP disease (HR, 1.19; 95% CI, 0.88–1.63). Despite these results, notable limitations included the omission of a third arm in which participants received a PARPi alone and, as such, questions regarding the true as well as the &lt;i&gt;quantitative effectiveness&lt;/i&gt; of bevacizumab plus olaparib versus treatment with olaparib alone remained unanswered. The only data to suggest a possible benefit to the combination come from an indirect comparison&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; of SOLO-1 and PAOLA-1, and the study suggested that adding bevacizumab to olaparib was associated with a &lt;i&gt;numerical&lt;/i&gt;, although not statistically significant, improvement in PFS (HR, 0.71; 95% CI, 0.45–1.09).&lt;/p&gt;&lt;p&gt;In this issue of &lt;i&gt;CA: A Cancer Journal for Clinicians&lt;/i&gt;, we get the results of FZOCUS-1, a randomized trial testing a PARPi, fuzuloparib, with a VEGFi, apatinib, as maintenance treatment after first-line therapy in ovarian cancer.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; Participants were stratified by the presence or absence of germline &lt;i&gt;BRCA1&lt;/i&gt; or &lt;i&gt;BRCA2&lt;/i&gt; mutation and by response to primary treatment. They were randomly assigned 2:2:1 to one of three maintenance arms: fuzuloparib plus apatanib, fuzuloparib plus placebo, or placebo plus placebo.&lt;/p&gt;&lt;p&gt;Compared with placebo, treatment with either fuzuloparib plus placeb","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70057","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148071332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus self-collection: The long road from scientific evaluation to implementation in screening programs","authors":"Nicolas Wentzensen MD, PhD, MS,&nbsp;Armando Baena MSc, PhD","doi":"10.3322/caac.70047","DOIUrl":"10.3322/caac.70047","url":null,"abstract":"&lt;p&gt;The understanding that persistent infections with human papillomavirus (HPV) cause nearly all cervical cancers has led to important cervical cancer prevention approaches: HPV vaccination is highly efficacious at preventing HPV infection when administered before infection occurs. In cervical cancer screening, HPV testing has higher sensitivity, provides longer reassurance when a test is negative, and has an overall better tradeoff of benefits and harms compared with cytology.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Consequently, HPV testing is gradually replacing cytology as a primary screening test in screening programs worldwide.&lt;/p&gt;&lt;p&gt;An additional benefit of HPV testing is that it can be conducted from self-collected vaginal specimens, with high concordance to clinician collected specimens. The article by Perkins et al.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; describes the adoption of clinical guidelines for HPV self-collection developed by the Enduring Guidelines effort&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; for the American Cancer Society cervical cancer screening guideline.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Using self-collected specimens for cervical cancer screening has great promise to expand screening to unscreened and underscreened populations who may not have access to clinician-based sampling or who may decide not to participate in screening to avoid pelvic examinations.&lt;/p&gt;&lt;p&gt;HPV self-collection is not a new development—the first studies evaluating self-collection were conducted in the 1990s and focused on different sampling strategies, including vaginal lavages, tampon collections, and vaginal brush devices.&lt;span&gt;&lt;sup&gt;6-9&lt;/sup&gt;&lt;/span&gt; Of these, vaginal sampling devices were the most successful and have become the standard for HPV self-collection today. More recently, urine-based HPV testing has been evaluated as a possible alternative to clinician and brush-based self-collection, with heterogeneous efficacy results to date.&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Since the initial proof-of-concept studies, HPV self-collection has been evaluated in many, mostly cross-sectional studies, as summarized in a series of systematic reviews.&lt;span&gt;&lt;sup&gt;11-14&lt;/sup&gt;&lt;/span&gt; The systematic reviews demonstrate that polymerase chain reaction (PCR)-based HPV tests have high agreement for detection of HPV and cervical precancer between clinician-collected and self-collected specimens. They have also demonstrated the high acceptability of HPV self-collection, with several studies indicating that screening participants prefer self-collection over clinician-collection. There is strong evidence that high sensitivity for precancer detection using self-collected samples is only achieved with PCR-based HPV DNA tests, as opposed to signal amplification or messenger RNA-based tests, which are not considered equivalent. Several components need to be considered when evaluating HPV self-collection, including the type of HPV assay, the type of collection device, the type of storage until processing (e.g., dry s","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70047","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for cervical cancer","authors":"","doi":"10.3322/caac.70049","DOIUrl":"10.3322/caac.70049","url":null,"abstract":"&lt;p&gt;The American Cancer Society (ACS) has updated its guideline recommendations for cervical cancer screening. The &lt;i&gt;cervix&lt;/i&gt; is the bottom part of the uterus that connects it to the vagina. Regular screening for precancerous changes can greatly lower your chances of developing cervical cancer. This update reflects new research and advances in medical testing, and it builds on the previous ACS cervical cancer screening guideline from 2020.&lt;/p&gt;&lt;p&gt;If any of these apply to you, talk to your health care provider about screening and the right test for you.&lt;/p&gt;&lt;p&gt;The goal of cervical cancer screening is to find any abnormal conditions early so they can be treated before they develop into cancer. Screening can also find cervical cancer at an early stage when it is easier to treat.&lt;/p&gt;&lt;p&gt;There are two types of tests for cervical cancer screening.&lt;/p&gt;&lt;p&gt;Some HPV tests are approved to be used only as part of a &lt;i&gt;co-test&lt;/i&gt;, that is, when an HPV test and a Pap test are done at the same time. Doing a co-test does not add much benefit compared with HPV testing alone. But a primary HPV test (HPV alone) may not be available in some settings, so co-testing every 5 years is still acceptable for screening. The sample for co-testing must be collected from the cervix by a health professional the same way it is done for a Pap test.&lt;/p&gt;&lt;p&gt;If none of the options for HPV testing are available, screening using only a Pap test is acceptable. Although all the screening tests are good at finding cancer and precancer, the primary HPV test finds more abnormal areas, and it finds them earlier than a Pap test done alone.&lt;/p&gt;&lt;p&gt;The most important thing to remember is to get screened regularly, no matter which test you get.&lt;/p&gt;&lt;p&gt;The US Food and Drug Administration (FDA) has now approved devices for people to collect their own samples from the vagina for HPV testing. Collecting vaginal samples can be done privately in a clinic setting, without the need for a health care provider present. An at-home self-collection kit is also available for use in some areas of the United States. If you choose to collect your own sample, a health care provider will need to order the test for you.&lt;/p&gt;&lt;p&gt;&lt;i&gt;Note: An HPV test that you can order yourself off the internet may not be good quality. ACS recommends using only FDA-approved tests and collection devices, and these are only available through your health care provider.&lt;/i&gt;&lt;/p&gt;&lt;p&gt;Although some people may be more comfortable with collecting a vaginal sample for HPV testing, tests done using a sample collected by a healthcare professional are still preferred. This is because, if your HPV test is positive on a sample that your provider collected from the cervix, the lab can run more tests on that same sample to determine the next steps for you. But if a self-collected HPV test shows abnormal results, you’ll need to see a health care provider, who will collect a new sample from the cervix for more testing.&lt;/p&gt;&lt;p&gt;The goal of cervical cancer scree","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 1","pages":""},"PeriodicalIF":232.4,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}